BackgroundThe superiority between remimazolam and propofol for anesthesia is controversial in elderly patients (≥60 years). This meta‐analysis aimed to systematically compare anesthetic effect and safety profile between remimazolam and propofol in elderly patients under any surgery.MethodsCochrane Library, Web of Science, and PubMed were searched until December 25, 2023 for relevant randomized controlled trials.ResultsTen studies with 806 patients receiving remimazolam (experimental group) and 813 patients receiving propofol (control group) were included. Time to loss of consciousness [standard mean difference (SMD) (95% confidence interval (CI): 1.347 (−0.362, 3.055), p = 0.122] and recovery time [SMD (95% CI): −0.022 (−0.300, 0.257), p = 0.879] were similar between experimental and control groups. Mean arterial pressure at baseline minus 1 min after induction [SMD (95% CI): −1.800 (−3.250, −0.349), p = 0.015], heart rate at baseline minus 1 min after induction [SMD (95% CI): −1.041 (−1.537, −0.545), p < 0.001], incidences of hypoxemia [relative risk (RR) (95% CI): 0.247 (0.138, 0.444), p < 0.001], respiratory depression [RR (95% CI): 0.458 (0.300, 0.700), p < 0.001], bradycardia [RR (95% CI): 0.409 (0.176, 0.954), p = 0.043], hypotension [RR (95% CI): 0.415 (0.241, 0.714), p = 0.007], and injection pain [RR (95% CI): 0.172 (0.113, 0.263), p < 0.001] were lower in the experimental group compared to the control group. Postoperative nausea and vomiting was not different between groups [RR (95% CI): 1.194 (0.829, 1.718), p = 0.341]. Moreover, this meta‐analysis displayed a low risk of bias, minimal publication bias, and good robustness.ConclusionRemimazolam shows comparative anesthetic effect and better safety profile than propofol in elderly patients under any surgery.